Biopharma Group Revenue and Competitors

Winchester, UK

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Biopharma Group's estimated annual revenue is currently $11.9M per year.(i)
  • Biopharma Group's estimated revenue per employee is $155,000

Employee Data

  • Biopharma Group has 77 Employees.(i)
  • Biopharma Group grew their employee count by 8% last year.

Biopharma Group's People

NameTitleEmail/Phone
1
Head MarketingReveal Email/Phone
2
Director R&DReveal Email/Phone
3
Group Quality Assurance ManagerReveal Email/Phone
4
Production ManagerReveal Email/Phone
5
Technical Manager - ConsultancyReveal Email/Phone
6
Global Commercial ManagerReveal Email/Phone
7
Technical Manager - InstrumentsReveal Email/Phone
8
Service EngineerReveal Email/Phone
9
Sales development and Courses ExecutiveReveal Email/Phone
10
Sales ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.5M29-12%N/AN/A
#2
$15.7M1015%N/AN/A
#3
$87.9M40525%$292MN/A
#4
$2.6M47016%$631.7MN/A
#5
$14.9M96-8%$81MN/A
#6
$44.8M2310%$132.9MN/A
#7
$7.6M49-37%N/AN/A
#8
$17.4M11212%N/AN/A
#9
$334.6M134911%£994.6MN/A
#10
$830.2M53568%N/AN/A
Add Company

What Is Biopharma Group?

Biopharma Group has several dedicated divisions covering the UK, France, Ireland and USA. Our aim is to meet the needs of our customers' projects appropriate to the size and stage by augmenting their in-house expertise whether for a single cycle run, individual analysis or a complete formulation development programme. Equipment Sales & Service: Established in 1989, this division is a leading supplier of equipment to pharmaceutical, biotech & process industries in the UK, Ireland and France, with a specialisation in freeze drying & associated technologies from volumetric powder fillers to aseptic processing lines. The key to our success is many years of experience & expertise in the processing industries plus our in-depth knowledge of the equipment we supply. We have an experienced technical service department enabling us to support the working life of your equipment. R&D Consultancy and Lab Analysis Services: In 1997 our R&D consultancy & lab analysis division was created to provide unbiased contract research, analysis & development services, training and analytical instrumentation to the global biopharmaceutical & related industries. We offer a uniquely comprehensive service & training courses (scheduled, customized, on-site or webinar) covering all aspects of freeze drying technology from pre-formulation through to full-scale production & dried product analysis and remains at the forefront of analytical instrumentation development, having launched the Lyostat5 & Lyotherm3 in 2016. Biopharma Technologies France (BTF) offers a combined proposition of equipment sales plus the expertise of the consultancy division giving our French-speaking clients a one-stop option. Biopharma Technology LLC (USA) concentrates on providing analytical instruments, lab services and training courses whilst BPS Crowthorne in Ireland combines the expertise offered by Biopharma with that of Crowthorne Hi-Tec Services, who are the UK's largest cleanroom validation service providers.

keywords:N/A

N/A

Total Funding

77

Number of Employees

$11.9M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Biopharma Group News

2022-04-20 - These lives matter': Oxfam and partners urge J&J, Pfizer and ...

In researching this report, the Fierce Pharma team relied on company filings, FDA records and our own archives. The team also utilized outside...

2022-04-19 - Glaxo gets a Shingrix boost

As Covid fades and Glaxosmithkline prepares to become a pure-play biopharma group, it needs its core franchises to deliver.

2022-04-19 - GSK's ViiV, Pfizer and Roche score high with COVID patient ...

The pharma industry is still holding on to its COVID-19 halo in the eyes of patient advocacy groups, according to the latest PatientView...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.6M784%N/A
#2
$3.5M817%N/A
#3
$24.1M8314%N/A
#4
$7.5M87-21%N/A
#5
$1.7M8816%N/A